Last reviewed 2026-05-14 · How we verify

Debecacin (DIBEKACIN)

FDA-approved active Small molecule Quality 15/100

Debecacin (generic name: DIBEKACIN) is a dibekacin drug. It is currently FDA-approved.

Debecacin, also known as DIBEKACIN, is a small molecule antibiotic belonging to the dibekacin drug class. Its target and approved indications are currently unknown. Debecacin has a half-life of 2.4 hours, but its bioavailability and commercial status are not well-documented. Further research is needed to fully understand its pharmacological properties and clinical applications.

At a glance

Generic name	DIBEKACIN
Drug class	dibekacin
Target	Macrolide 2'-phosphotransferase II; Macrolide 2'-phosphotransferase II protein MphB; Macrolide 2-phosphotransferase, mph(B)
Modality	Small molecule
Therapeutic area	Infectious Disease
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Early-onset Ventilator-associated Pneumonia in Adults: Comparison of 8 Versus 15 Days of Antibiotic Treatment (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Debecacin CI brief — competitive landscape report
Debecacin updates RSS · CI watch RSS

Frequently asked questions about Debecacin

What is Debecacin?

Debecacin (DIBEKACIN) is a dibekacin drug.

What is the generic name of Debecacin?

DIBEKACIN is the generic (nonproprietary) name of Debecacin.

What drug class is Debecacin in?

Debecacin belongs to the dibekacin class. See all dibekacin drugs at /class/dibekacin.

What development phase is Debecacin in?

Debecacin is FDA-approved (marketed).

What does Debecacin target?

Debecacin targets Macrolide 2'-phosphotransferase II; Macrolide 2'-phosphotransferase II protein MphB; Macrolide 2-phosphotransferase, mph(B) and is a dibekacin.

Drug class: All dibekacin drugs
Target: All drugs targeting Macrolide 2'-phosphotransferase II; Macrolide 2'-phosphotransferase II protein MphB; Macrolide 2-phosphotransferase, mph(B)
Therapeutic area: All drugs in Infectious Disease

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing